Pharma stock Sigachi sees profit booking after rising 8% intraday on announcing API breakthrough

Stock sees profit booking.

Shares of smallcap Sigachi Industries witnessed profit booking on Thursday after rising nearly 8 percent in early trade following the announcement of a research and development milestone in active pharmaceutical ingredients (APIs).

The pharma stock climbed as much as 8 percent to Rs 25.50 per share on the NSE during intraday trade. However, the gains were short-lived, and the shares later pared most of the advance to trade at Rs 23.05, down nearly 2 percent.

The early surge came after the company informed exchanges about the successful advancement of a new Cystic Fibrosis (CF) API combination comprising Vanzacaftor, Tezacaftor and Deutivacaftor.

"The development marks an important step in Sigachi’s strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments," the company said in an exchange filing.

The company said it is exploring strategic collaborations with formulation innovators for research and development and future commercial supply of the CF APIs. The company estimates a revenue potential of around Rs 250 crore per annum, starting from the fourth quarter of 2026-27.

The company is a constituent of the S&P BSE SmallCap index. According to BSE data, the stock has corrected over 50 percent in the past one year and nearly 70 percent over the last two years.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.